http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015245998-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_900312cdc5f314d208e7daa6a218640f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18726312eff9eb2bd2f380dd8189ec20 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4825 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4891 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate | 2015-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efd224e745f7f56dd8484f10e677ba4e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88e365824ae6c90fb209976dcecfff1d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43b09fddff3fc8221768b98850aaa952 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_060263483c7bef7e8f2c8653010bc903 |
| publicationDate | 2015-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2015245998-A1 |
| titleOfInvention | Doxycycline Formulations, and Methods of Treating Rosacea |
| abstract | The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean C max of the pharmaceutical composition is within 80.00% to 125.00% of a C max value of 510±220.7 ng/mL, after administration of a single dose of the pharmaceutical composition to humans in a fasting state; and wherein the relative mean AUC (0-∞) of the pharmaceutical composition is within 80.00% to 125.00% of a AUC (0-∞) value of 9227±3212.8 ng·hr/mL, after administration of a single dose of the pharmaceutical composition to humans in a fasting state. |
| priorityDate | 2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.